The estimated Net Worth of James T Lafrance is at least $1.32 Milion dollars as of 14 August 2018. Mr. Lafrance owns over 23,400 units of Vermillion stock worth over $1,192,072 and over the last 11 years he sold VRML stock worth over $11,700. In addition, he makes $120,000 as Independent Chairman of the Board at Vermillion.
James has made over 5 trades of the Vermillion stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 23,400 units of VRML stock worth $11,700 on 14 August 2018.
The largest trade he's ever made was buying 41,615 units of Vermillion stock on 18 November 2014 worth over $59,509. On average, James trades about 4,147 units every 49 days since 2014. As of 14 August 2018 he still owns at least 298,018 units of Vermillion stock.
You can see the complete history of Mr. Lafrance stock trades at the bottom of the page.
James T. LaFrance serves as Independent Chairman of the Board of the Company., since January 1, 2015. was appointed to our Board in December 2013 and was also appointed Chairman of our Board. Mr. LaFrance was initially designated as a director nominee pursuant to the Stockholders Agreement described under “Certain Relationships and Related Transactions” below. He also served as our President and Chief Executive Officer from April 2014 to December 2014. Mr. LaFrance has over thirty years of diagnostic industry experience. From May 2012 to September 2013, Mr. LaFrance was head of digital pathology and acting Chief Executive Officer of Omnyx, LLC for GE Healthcare, a medical technology provider. From 2009 to 2011, Mr. LaFrance was the President and Chief Executive Officer of LaFrance Consulting, an independent consulting firm. Prior to that, Mr. LaFrance held a series of commercial, strategic marketing and business development leadership roles at Ventana Medical Systems, Inc. (now Roche Tissue Diagnostics), a provider of tissue-based diagnostic solutions, including general manager of their North American and International commercial organizations from 2001 to 2009. Prior to Ventana, Mr. LaFrance served in leadership roles in strategic marketing and business development at Bayer Diagnostics. He currently serves as a member of the boards of HTG Molecular, Inc., and Personal Genome Diagnostics, Inc. He earned a Bachelor of Arts degree in Economics from the University of Connecticut and an M.B.A. from the University of Notre Dame. Our Board has determined that based upon Mr. LaFrance’s demonstrated executive-level management and commercial operations skills, as well as his prior role as our President and Chief Executive Officer and his prior board position, he has the qualifications and skills to serve as a member and the Chairman of our Board.
As the Independent Chairman of the Board of Vermillion, the total compensation of James LaFrance at Vermillion is $120,000. There are 3 executives at Vermillion getting paid more, with Valerie Palmieri having the highest compensation of $941,832.
James LaFrance is 61, he's been the Independent Chairman of the Board of Vermillion since 2015. There are 2 older and 4 younger executives at Vermillion. The oldest executive at Vermillion, Inc. is James Burns, 73, who is the Independent Director.
James's mailing address filed with the SEC is C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON, AZ, 85706.
Over the last 17 years, insiders at Vermillion have traded over $1,008,376 worth of Vermillion stock and bought 29,557,130 units worth $34,088,488 . The most active insiders traders include Jack W Schuler, Henri George Schuler a Larry Noracle Partners Lp F.... On average, Vermillion executives and independent directors trade stock every 59 days with the average trade being worth of $1,572,028. The most recent stock trade was executed by Robert Harry Beechey on 15 November 2019, trading 5,000 units of VRML stock currently worth $3,550.
Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
Vermillion executives and other stock owners filed with the SEC include: